calcifediol; 25-OH cholcalciferol; 25-OH vitamin D3 (Calderol)

Introduction

Tradename: Calderol.

Indications

• metabolic bone disease
• hypocalcemia in patients with renal failure
• vitamin D deficiency
• hypophosphatemia (VITAMIN_D_DEFICIENCY HYPOPHOSPHATEMIA)

Dosage

• 300-350 ug/week administered daily or on alternate days (50 ug PO QD)
• dose may be increased at 4 week intervals if adequate response is not observed

Pharmacokinetics

• readily absorbed from intestine
• absorption may be reduces by liver or biliary disease or steatorrhea
• 1/2life of several weeks (conflict, see misc info)

elimination via liver

1/2life = 3-6 hours

Adverse effects

• weakness
• headache
• somnolence
• nausea/vomiting
• dry mouth
• constipation
• late adverse effects
  • polyuria
  • polydipsia
  • irritability
  • weight loss

Drug interactions

• antacids: hypermagnesemia may result in patients with renal failure
• cholestyramine & colestipol may decrease effect of calcifediol

• drug interaction(s) of statins with vitamin D

Mechanism of action

• vitamin D3 is hydroxylated in the liver to form 25-OH vit D3
• 25-OH vitamin D3 is hydroxylated in the kidney to form 1,25- dihydroxy vitamin D3 (calcitriol), the active metabolite of vitamin D3
• calcitriol stimulates intestinal Ca+2 & phosphate transport
• 25-OH vitamin D is the major circulating form of vitamin D; it has only mild biologic activity.

More general terms

• cholecalciferol; vitamin D3

Additional terms

• 25-hydroxyvitamin D3 (calcifediol) in serum
• vitamin D binding protein, Gc globulin; group-specific component

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=166583
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5283731
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5282368
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=29553
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=1593